Boston Scientific Corp (BSX)vsHaemonetics Corporation (HAE)
BSX
Boston Scientific Corp
$48.55
+0.76%
HEALTHCARE · Cap: $69.50B
HAE
Haemonetics Corporation
$71.28
+2.05%
HEALTHCARE · Cap: $3.55B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 1445% more annual revenue ($20.61B vs $1.33B). BSX leads profitability with a 17.3% profit margin vs 7.3%. BSX appears more attractively valued with a PEG of 0.57. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
HAE
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-25.6%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Margin of Safety
+33.9%
Fair Value
$86.95
Current Price
$71.28
$15.67 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Earnings expanding 28.4% YoY
Areas to Watch
No major concerns identified
Premium valuation, high expectations priced in
4.8% revenue growth
Distress zone — elevated risk
7.3% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : HAE
The strongest argument for HAE centers on EPS Growth. PEG of 1.25 suggests the stock is reasonably priced for its growth.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : HAE
The primary concerns for HAE are P/E Ratio, Revenue Growth, Altman Z-Score. Debt-to-equity of 1.54 is elevated, increasing financial risk.
Key Dynamics to Monitor
BSX profiles as a mature stock while HAE is a value play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.56 — expect wider price swings.
BSX is growing revenue faster at 11.6% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 56/100), backed by strong 17.3% margins and 11.6% revenue growth. HAE offers better value entry with a 33.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Haemonetics Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?